These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29424288)

  • 1. The Ellipta
    Jones TL; Neville DM; Chauhan AJ
    Ther Deliv; 2018 Feb; 9(3):169-176. PubMed ID: 29424288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
    Grant AC; Walker R; Hamilton M; Garrill K
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI.
    Yun Kirby S; Zhu CQ; Kerwin EM; Stanford RH; Georges G
    COPD; 2016; 13(2):167-75. PubMed ID: 26516724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.
    Svedsater H; Dale P; Garrill K; Walker R; Woepse MW
    BMC Pulm Med; 2013 Dec; 13():72. PubMed ID: 24314123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.
    van der Palen J; Thomas M; Chrystyn H; Sharma RK; van der Valk PD; Goosens M; Wilkinson T; Stonham C; Chauhan AJ; Imber V; Zhu CQ; Svedsater H; Barnes NC
    NPJ Prim Care Respir Med; 2016 Nov; 26():16079. PubMed ID: 27883002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD.
    van der Palen J; Moeskops-van Beurden W; Dawson CM; James WY; Preece A; Midwinter D; Barnes N; Sharma R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2515-2523. PubMed ID: 30174421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.
    Hantulik P; Wittig K; Henschel Y; Ochse J; Vahteristo M; Rytila P
    Pneumonol Alergol Pol; 2015; 83(5):365-77. PubMed ID: 26378998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences.
    Ninane V; Vandevoorde J; Cataldo D; Derom E; Liistro G; Munghen E; Peché R; Schlesser M; Verleden G; Vincken W
    Respir Med; 2015 Nov; 109(11):1430-8. PubMed ID: 26439177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Satisfaction, preference and error occurrence of three dry powder inhalers as assessed by a cohort naïve to inhaler operation.
    Man KN; Tian Z; Lam DC; Wan JMF; Tan-Un KC
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1949-1963. PubMed ID: 29942127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.
    Altman P; Wehbe L; Dederichs J; Guerin T; Ament B; Moronta MC; Pino AV; Goyal P
    BMC Pulm Med; 2018 Jun; 18(1):100. PubMed ID: 29898702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver.
    Weers J; Ung K; Le J; Rao N; Ament B; Axford G; Maltz D; Chan L
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):56-68. PubMed ID: 22691109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Device errors in asthma and COPD: systematic literature review and meta-analysis.
    Chrystyn H; van der Palen J; Sharma R; Barnes N; Delafont B; Mahajan A; Thomas M
    NPJ Prim Care Respir Med; 2017 Apr; 27(1):22. PubMed ID: 28373682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correct use and ease of use of a placebo dry powder inhaler in subjects with asthma and chronic obstructive pulmonary disease.
    Feldman GJ; Galkin DV; Patel P; Collison KA; Sharma R
    Chron Respir Dis; 2019; 16():1479973118815692. PubMed ID: 30789018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
    Molimard M; Till D; Stenglein S; Singh D; Krummen M
    Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study.
    Virchow JC; Weuthen T; Harmer QJ; Jones S
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1849-57. PubMed ID: 25151851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
    Henriet AC; Marchand-Adam S; Mankikian J; Diot P
    Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.